Years of life lost and long-term outcomes due to glomerular disease in a Southeast Asian Cohort.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 11 2023
05 11 2023
Historique:
received:
21
04
2023
accepted:
30
10
2023
medline:
7
11
2023
pubmed:
6
11
2023
entrez:
5
11
2023
Statut:
epublish
Résumé
Death and end-stage kidney disease (ESKD) are major outcomes of glomerular disease. (GD) The years of potential life lost (YLL) may provide additional insight into the disease burden beyond death rates. There is limited data on premature mortality in GD. In this retrospective observational cohort study, we evaluated the mortality, ESKD rates, and YLL in Thais with biopsy-proven GD. The mortality and combined outcome rates were determined by log-rank test and ESKD by using a competing risk model. YLL and premature life lost before age 60 were calculated for different GD based on the life expectancy of the Thai population. Patients with GD (n = 949) were followed for 5237 patient years. The death rate and ESKD rates (95%CI) were 4.2 (3.7-4.9) and 3.3 (2.9-3.9) per 100 patient-years, respectively. Paraprotein-related kidney disease had the highest death rate, and diabetic nephropathy had the highest ESKD rate. Despite not having the highest death rate, lupus nephritis (LN) had the highest YLL (41% of all GD) and premature loss of life before age 60. In conclusion, YLL provided a different disease burden assessment compared to mortality rates and identified LN as the major cause of premature death due to GD in a Southeast Asian cohort.
Identifiants
pubmed: 37926743
doi: 10.1038/s41598-023-46268-9
pii: 10.1038/s41598-023-46268-9
pmc: PMC10625977
doi:
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19119Informations de copyright
© 2023. The Author(s).
Références
Kidney Dis (Basel). 2019 Oct;5(4):247-258
pubmed: 31768382
Int Urol Nephrol. 2022 Sep;54(9):2365-2373
pubmed: 35152346
Br J Cancer. 2014 Aug 26;111(5):1014-20
pubmed: 24983370
Semin Nephrol. 2003 Mar;23(2):172-82
pubmed: 12704577
Nephrology (Carlton). 2021 Feb;26(2):142-152
pubmed: 33169890
Clin J Am Soc Nephrol. 2020 May 7;15(5):673-684
pubmed: 32354728
Clin J Am Soc Nephrol. 2013 Nov;8(11):2007-17
pubmed: 23868898
Eur J Clin Invest. 2014 Jun;44(6):578-86
pubmed: 24749685
Clin J Am Soc Nephrol. 2012 Sep;7(9):1401-8
pubmed: 22798538
Lancet. 2015 May 16;385(9981):1975-82
pubmed: 25777665
Mayo Clin Proc. 2018 Feb;93(2):167-178
pubmed: 29395351
Nat Rev Nephrol. 2013 Sep;9(9):500-12
pubmed: 23856995
Contemp Oncol (Pozn). 2020;24(1):13-16
pubmed: 32514233
Lancet. 2022 Apr 23;399(10335):1646-1663
pubmed: 35461559
Kidney Int Suppl (2011). 2022 Apr;12(1):7-11
pubmed: 35529086
Ann Rheum Dis. 2020 Jun;79(6):713-723
pubmed: 32220834
Lupus. 2014 Dec;23(14):1546-52
pubmed: 25209070
Kidney Int. 2017 Aug;92(2):388-396
pubmed: 28577854
Nephrol Dial Transplant. 1999 Aug;14(8):1889-97
pubmed: 10462267
Sci Rep. 2020 Jul 3;10(1):10994
pubmed: 32620914
Sci Rep. 2021 Feb 18;11(1):3504
pubmed: 33603008
Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1662-1663
pubmed: 27605595
Semin Nephrol. 2022 Sep;42(5):151316
pubmed: 36773418
J Med Assoc Thai. 2006 Aug;89 Suppl 2:S106-11
pubmed: 17044461
Nephrol Dial Transplant. 2019 Feb 1;34(2):193-199
pubmed: 30124958
Kidney Int. 2016 Oct;90(4):853-60
pubmed: 27425855
Clin Kidney J. 2020 Nov 03;14(6):1594-1602
pubmed: 34084455
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Diabetes Obes Metab. 2020 Apr;22 Suppl 1:3-15
pubmed: 32267079
Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1170-8
pubmed: 26092830
Kidney Int. 2018 Sep;94(3):567-581
pubmed: 30078514
J Nephrol. 2016 Aug;29(4):479-86
pubmed: 26842624
Am J Nephrol. 2008;28(4):569-75
pubmed: 18239383
Am J Nephrol. 2013;37(1):74-83
pubmed: 23343855
Am J Kidney Dis. 2022 Dec;80(6):740-750
pubmed: 35659570
Kidney Int Rep. 2017 Aug 24;3(1):99-104
pubmed: 29340319